Anasarca Workup and Management

Immediate Assessment and Laboratory Workup

The American College of Cardiology recommends rapidly assessing for life-threatening hemodynamic instability, including hypotension, tachycardia, abnormal respiratory effort, and low oxygen saturation, as these findings require immediate intervention 1
Evaluate for signs of hypoperfusion, such as cold extremities, oliguria, mental confusion, dizziness, and narrow pulse pressure, to identify patients at risk of cardiac or renal failure 1
Assess for bilateral pulmonary rales, orthopnea, and paroxysmal nocturnal dyspnea, suggesting left-sided heart failure, and examine jugular venous pressure (JVP) to improve the specificity of edema as a sign of congestion 1
The European Society of Cardiology suggests ordering a comprehensive metabolic panel, complete blood count, cardiac biomarkers (BNP or NT-proBNP), urinalysis with microscopy, and quantification of proteinuria as the core initial laboratory assessment 1
Complete blood count is essential to assess for anemia, which may exacerbate heart failure, and comprehensive metabolic panel, including electrolytes, BUN, creatinine, to assess renal function 1
Cardiac biomarkers (BNP or NT-proBNP and troponins) are crucial to differentiate cardiac from non-cardiac causes of anasarca 1
Urinalysis with microscopic examination and quantification of proteinuria (24-hour urine protein or spot protein-to-creatinine ratio) are necessary to evaluate renal function and detect proteinuria 1, 2

Obtain a chest X-ray and 12-lead ECG immediately, followed by echocardiography within 48 hours, to assess cardiac function and detect potential causes of anasarca 1
Echocardiography within 48 hours is essential to assess left and right ventricular function, ejection fraction, valvular abnormalities, and pericardial disease 1
The American Heart Association recommends looking for history of coronary artery disease, hypertension, or valvular disease, and elevated BNP/NT-proBNP levels (>400 pg/mL for BNP, >900 pg/mL for NT-proBNP in acute settings) to diagnose cardiac causes of anasarca 1
Reduced ejection fraction (<40%) or preserved ejection fraction with diastolic dysfunction on echocardiography suggests cardiac dysfunction 1
Massive proteinuria (>3.5 g/day) suggests nephrotic syndrome, and history of kidney disease or recent acute kidney injury is essential to diagnose renal causes of anasarca 3

In patients with profound anasarca and hemodynamic compromise, consider the need for albumin infusions via central venous line and intensive monitoring in a specialized unit, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 3
Avoid peripherally inserted catheters and unnecessary venepunctures to preserve vascular access, and consider genetic testing in infants or young children with congenital nephrotic syndrome 3
Failing to measure body weight consistently for monitoring fluid status, overlooking non-cardiac causes of anasarca, delaying echocardiography beyond 48 hours, and inadequate assessment of volume status using only clinical examination without laboratory parameters are common pitfalls to avoid 1

The American Thoracic Society suggests that in patients with severe anasarca and hemodynamic compromise, consider cautious medication titration, starting at reduced infusion rates, as a model for diuretic dosing, with a strength of evidence based on expert opinion 4
For patients with coronary artery disease, hypertension, or valvular disease, the American College of Chest Physicians recommends continuing aggressive loop diuretic therapy and adding ACE inhibitors or ARBs for blood pressure control and cardiac remodeling, with consideration of beta-blockers once euvolemia is achieved, based on moderate-quality evidence 4
In patients with hepatic causes of anasarca, such as elevated liver enzymes and low albumin, the American Association for the Study of Liver Diseases suggests adding spironolactone to the furosemide regimen and restricting sodium intake to <2 g/day, with monitoring for hepatorenal syndrome, based on low-quality evidence 4

In patients with severe edema, there is no need to slow down the rate of daily weight loss, as aggressive loop diuretic therapy is the cornerstone of treatment 5, 6
The use of a stepped-care approach starting with spironolactone, increasing from 100 mg/day to 400 mg/day, is recommended for hepatic causes of anasarca 5, 6
The simultaneous administration of furosemide and spironolactone increases the natriuretic effect, and once edema resolves but ascites persists, slow the rate of weight loss 5, 6
Consider therapeutic paracentesis for large volume ascites with albumin infusion (8 g/litre of ascites removed) 5, 6

Monitor volume status using daily body weights, central venous pressure or pulmonary wedge pressure in severe cases, and fluid balance calculations 5, 6
Adjust diuretic doses based on response, and furosemide can be increased every 2-3 days up to 160 mg/day, though high doses require cautious monitoring for electrolyte disturbances and metabolic alkalosis 6

Over-diuresis leading to intravascular volume depletion, renal impairment, hepatic encephalopathy, and hyponatremia can occur, and it is essential to check compliance with sodium restriction by measuring urinary sodium excretion 5, 6
Using large volumes of hypotonic fluids is contraindicated 7, 8

In patients with hemodynamic compromise, start diuretics at reduced infusion rates and titrate cautiously, and for argatroban dosing in ECMO patients with anasarca, use substantially lower starting doses of 0.5-1.2 μg/kg/min rather than the standard 2 μg/kg/min 9